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Abstract
Purpose
To examine the value of surveillance urethro-cystoscopy in patients with neurogenic lower
urinary tract dysfunction (NLUTD) in regard to the conflicting literature as it is generally
agreed that patients with NLUTD are at increased risk for bladder cancer.
Materials and Methods
In a cross-sectional study, a consecutive series of 129 patients (50 females, 79 males,
mean age 51, range 18–88) suffering from NLUTD for at least 5 years was prospectively
investigated using urethro-cystoscopy and bladder washing cytology at a single university
spinal cord injury (SCI) center.
Results
Due to suspicious urethro-cystoscopy and/or bladder washing cytology findings, 13 (10%)
of 129 patients underwent transurethral resection of the bladder lesion and/or random blad-
der biopsies. Overall, 9 relevant histological findings were found in 5% (7/129) of our
patients: bladder melanosis (n = 1), nephrogenic adenoma (n = 3), keratinizing squamous
metaplasia (n = 1), intestinal metaplasia (n = 3), and muscle-invasive adenocarcinoma of
the bladder (n = 1).
Conclusions
Using surveillance urethro-cystoscopy, we found relevant histological findings in 5% of our
patients suffering from NLUTD for at least 5 years. Thus, surveillance urethro-cystoscopy
might be warranted, although the ideal starting point and frequency remain to be determined
in further prospective studies.
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Introduction
Bladder cancer, as defined by the 10th revision of the International Classification of Diseases
(ICD-10) [1], is a common neoplasia in the general population with a recently reported inci-
dence of 151 and a mortality of 52 per 100’000 adults in Europe for the year 2012 [2]. Men are
more frequently affected than women with a higher incidence ratio ranging between 1.3 and
6.3 [3]. In men, bladder cancer is the sixth leading cancer worldwide [4]. There are several risk
factors associated with bladder cancer, that is, tobacco smoking, increased age, male gender,
chronic bladder infection, chronic irritation from indwelling catheters, and exposure to aro-
matic amines, polycyclic aromatic hydrocarbons and chlorinated hydrocarbons, benzole,
cyclophosphamide and radiation [5]. It is generally agreed that patients with neurogenic lower
urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI) are at increased risk for
bladder cancer [6]. However, there is no consensus on the type and frequency of investigations
to detect urological malignancies at an early stage in patients suffering from NLUTD and there
is a lack of specific recommendations in the guidelines of the American Urological Association
(AUA) and European Association of Urology (EAU) to address this issue. Considering the
conflicting literature, we aimed to examine the value of surveillance urethro-cystoscopy in
patients with NLUTD due to different neurological disorders including SCI.
Materials and Methods
Patients
From January 2011 to November 2013, a consecutive series of 129 patients suffering from
NLUTD for at least 5 years was prospectively investigated in a cross-sectional study using ure-
thro-cystoscopy and bladder washing cytology at the SCI Center, University of Zürich, Balgrist
University Hospital, Zürich, Switzerland. Study exclusion criteria was current urinary tract
infection (UTI), gross hematuria and age<18 years. This study was approved by the local eth-
ics committee, i.e. Kantonale Ethikkommision (KEK) Zürich, Switzerland; study identification
number: KEK-ZH-NR: 2010-0207/0 and all patients provided written informed consent
according to the Helsinki II declaration.
Investigations
According to the EAU guidelines, urethro-cystoscopy and bladder washing cytology are both
established routine follow-up investigations for patients with NLUTD [5]. At our department,
we performed both in addition to a widespread neuro-urological evaluation that includes renal
ultrasound and urodynamics. Furthermore, we obtained the medical history, in particular the
method of bladder management and the exposure to risk factors for developing bladder cancer
such as tobacco smoking, aromatic amines, polycyclic aromatic hydrocarbons, chlorinated
hydrocarbons, ionizing radiation, cyclophosphamide, pioglitazone [5].
Patients with a UTI were excluded and adequately treated according to the antibiotic sensi-
tivity pattern before urethro-cystoscopy. For local anesthesia, lidocaine gel (Instillagel1 2x 10
mL, Farco-Pharma GmbH, Germany) was instilled into the urethra and exposed for 10 min-
utes. Urethro-cystoscopy was performed in a lithotomy or supine position using a rigid or flex-
ible cystoscope in women and men, respectively. After urethro-cystoscopy, we routinely
performed a bladder washing cytology. In the case of suspicious urethro-cystoscopy and/or
bladder washing cytology findings, the patient was scheduled for transurethral resection of the
bladder (TUR-B) and/or random cold biopsies in spinal or general anesthesia. Histological and
cytological findings were reported by board certified pathologists and cytologists, respectively,
according to findings on routinely processed and stained specimen.
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Outcome Measure
The outcome measures were suspicious urethro-cystoscopy and/or bladder washing cytology
findings and relevant histological findings defined as bladder cancer or potentially premalig-
nant lesions.
Statistical Analysis
Data were normally distributed and are presented as mean and standard deviation (SD).
Descriptive statistical analyses were performed using IBM1 SPSS1 Statistics Version 19.
Results
Mean age of the 129 patients was 51 ± 16 years (range 18 to 88). 50 (39%) and 79 (61%) were
women and men, respectively. The cause of NLUTD was SCI in 89 patients (69%), multiple
sclerosis in 20 (16%), myelomeningocele in 8 (6%), cerebral palsy in 4 (3%) and other neuro-
logical disorders in 8 (6%). Patients’ characteristics are shown in Table 1.
Overall, 58 (45%) of the 129 patients were exposed to at least one risk factor for bladder can-
cer (Table 2). Due to suspicious urethro-cystoscopy and/or bladder washing cytology findings,
13 (10%) of the 129 patients underwent transurethral resection of the bladder lesion and/or
random bladder biopsies (Table 3). In total, 9 relevant histological findings were found in 5%
(7/129) of our patients: Bladder melanosis (n = 1, Fig 1), nephrogenic adenoma (n = 3, Fig 2),
keratinizing squamous metaplasia (n = 1, Fig 3), intestinal metaplasia (n = 3, Fig 4) and mus-
cle-invasive adenocarcinoma of the bladder (n = 1, Fig 5). The patient with bladder cancer
underwent bilateral pelvic lymphadenectomy and radical cystoprostatovesiculectomy with a
continent catheterizable reservoir and final histology revealed pT3b pN0 (0/15) cM0 G3
mucus-producing adenocarcinoma of the bladder.
Discussion
Using surveillance urethro-cystoscopy, we detected relevant histological findings in 5% of our
patients suffering from NLUTD for at least 5 years. Considering this important percentage of
clinically relevant findings, surveillance urethro-cystoscopy might be warranted, although the
Table 1. Patients’ characteristics.
Neurological disorder Number of patients
(females)
Age at cystoscopy in
years*
Duration of neurological disorder in
years*
Bladder
management
I II III
Spinal cord injury
(69%)
89 (25) 50±15 (18–88) 15±9 (5–45) 29 43 17 (10/
7)
Multiple sclerosis
(16%)
20 (16) 55±11 (36–73) 22±10 (6–47) 7 5 8 (8/0)
Myelomeningocele
(6%)
8 (3) 30±19 (21–75) 30±19 (21–75) 3 5 0
Cerebral palsy (3%) 4 (3) 56±8 (45–65) 56±8 (45–65) 3 0 1 (1/0)
Other (6%) 8 (3) 70±12 (49–88) 19±25 (5–80) 5 0 3 (3/0)
All 129 (50) 51±16 (18–88) 19±14 (5–80) 47 53 29 (22/
7)
Bladder management: I = Spontaneous voiding, II = Aseptic intermittent self-catheterization and III = Indwelling catheter (suprapubic/transurethral).
* Data presentation: mean ± standard deviation (range).
doi:10.1371/journal.pone.0140970.t001
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ideal patient population, starting point and frequency remain to be determined in further pro-
spective studies.
In comparison to the general population, an up to 25 times higher risk of developing blad-
der cancer has been reported in patients with SCI relying on chronic indwelling catheters [7].
This method of bladder management leads to chronic irritation of the bladder mucosa [8] and
chronic urinary tract infections (UTI) [6] while serving as an independent risk factor for blad-
der cancer in SCI patients [7]. Bladder cancer has been reported to be present in SCI patients at
a lower age and a higher stage, when diagnosed [6], compared to the general population.
Gross hematuria, a well-known phenomenon in SCI patients with indwelling catheters, has
a significantly higher incidence the longer the duration of catheterization is [9]. The initiation
of a routine screening protocol might be useful with the objective of minimizing morbidity and
mortality of bladder cancer in patients suffering from NLUTD, since typical clinical symptoms
of bladder cancer such as gross hematuria may be absent [9]. Although the literature is limited,
microscopic hematuria has been reported to be present in 15% of SCI patients [10]. Yet, the
specificity of urine dipstick is restricted as microscopic hematuria may result from various rea-
sons, that is calculi, infections or use of certain drugs [11]. Therefore, the interpretation of
microscopic hematuria is challenging in this population and needs a patient-tailored approach.
With no consensus on how to manage patients with NLUTD to detect urological malignan-
cies at an early stage, the need for establishing suitable diagnostic methods is substantial. Ultra-
sound of the bladder, a non-invasive diagnostic tool, is reported to be inferior to urethro-
cystoscopy in identifying bladder cancer in patients with hematuria [12] and therefore inap-
propriate to replace urethro-cystoscopy and bladder washing cytology. However, the role of
urethro-cystoscopy and bladder washing cytology for surveillance has not yet been clearly
determined and a cost-benefit analysis is still up for discussion regarding this challenging
patient population.
According to the consortium for spinal cord medicine [13], SCI patients should undergo an
extensive annual urological evaluation program including urethro-cystoscopic investigation in
addition to urodynamics to achieve a sufficient functional/anatomical assessment of the lower
urinary tract system. Navon et al. recommended the performance of annual urethro-cystos-
copy in SCI patients beginning 10 years after injury and in patients with recurrent or chronic
UTI resulting in the diagnosis of squamous cell bladder cancer at early stages with consecutive
increase of long-term survival [14]. Annual urethro-cystoscopy and urine cytology with routine
random biopsies every 1 to 2 years in individuals with SCI was advocated by Broecker et al.
Table 2. Patients’ exposure to risk factors for bladder cancer.
Neurological disorder Exposure to risk
factors*
Tobacco Aromatic
amines
Polycyclic aromatic
hydrocarbons
Chlorinated
hydrocarbons
Ionizing
radiation
Spinal cord injury
(n = 89)
45 (51%) 40 12 5 3 3
Multiple sclerosis
(n = 20)
5 (25%) 5 0 0 0 0
Myelomeningocele
(n = 8)
3 (38%) 1 1 1 0 0
Cerebral palsy (n = 4) 1 (25%) 1 0 0 0 0
Other (n = 8) 4 (50%) 3 1 0 0 2
All (n = 129) 58 (45%) 50 14 6 3 5
* Patients were exposed to at least one risk factor (multiple exposures possible).
doi:10.1371/journal.pone.0140970.t002
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Fig 1. Melanosis of the urothelium in a 56 years old woman (Table 3, Patient 12). A—Bladder washing
with dark brown and black pigment in urothelial cells (arrows) (Papanicolaou stain; original magnification
400x).B—Bladder mucosa biopsy containing dark brown and black pigment in urothelial cells of all levels
(arrows) (Hematoxylin and eosin stain; original magnification 400x).C—Negativity of the intraepithelial
pigment in an iron stain (arrow) excluding hemosiderin pigment deposits (Iron stain; original magnification
400x).
doi:10.1371/journal.pone.0140970.g001
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[10]. In contrast, Hamid et al. did not recommended routine surveillance urethro-cystoscopy
and biopsy in patients with a neuropathic bladder and chronic suprapubic indwelling catheters
due to high screening costs with low detection rate and associated morbidity [8]. Importantly,
there are no generally agreed recommendations regarding follow-up evaluation of the neuro-
urological patient and there is a complete lack of high-evidence level studies on this topic [15].
In an attempt to minimize morbidity caused by urethro-cystoscopy, antibiotic prophylaxis
might be considered in high-risk patients suffering from NLUTD in order to prevent symp-
tomatic UTI. In patients with SCI being at risk of the development of autonomic dysreflexia
due to bladder distension during urethro-cystoscopy might profit from using a less traumatic
flexible instead of a rigid cystoscope while being on continuous cardiovascular monitoring at
the same time, that is, blood pressure and heart rate [16]. To improve the detection rate of
Fig 2. Nephrogenic adenoma in a 21 years old woman (Table 3, Patient 10). Intraluminal polypoid mass
(arrow), covered by cylindrical non-dysplastic epithelium and containing bland glands, accompanied by some
inflammatory cells. The bladder mucosa at the base of the lesion (asterisk) shows chronic inflammation
(Hematoxylin and eosin stain; original magnification 25x).
doi:10.1371/journal.pone.0140970.g002
Fig 3. Extensive keratinizing squamousmetaplasia of the urothelium in a 43 years old man (Table 3, Patient 7). A—Bladder washing with numerous,
often anucleated squamous cells (arrows). Only rare, degenerated urothelial cells (arrowhead) and many neutrophils in the background (Papanicolaou stain;
original magnification 200x).B—On biopsy, bladder mucosa is covered by non-dysplastic squamous epithelium (black bracket) with a thick anucleated
keratinized superficial layer (white bracket) (Hematoxylin and eosin stain; original magnification 200x).
doi:10.1371/journal.pone.0140970.g003
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Fig 4. Intestinal metaplasia in a 45 years old woman (Table 3, Patient 11). Intestinal type glands in the
bladder biopsy (arrows). Denuded surface of the mucosa containing some inflammatory cells (Hematoxylin
and eosin stain; original magnification 50x).
doi:10.1371/journal.pone.0140970.g004
Fig 5. Mucinous adenocarcinoma in a 59 years old man (Table 3, Patient 8). Intraluminal polypoid mass
(asterisk) consisting of malignant glands with intra- and extracellular mucus and infiltrating growth. The arrow
points to the transition zone between urinary type epithelium and cylinder cells of the intestinal metaplasia
(Hematoxylin and eosin stain; original magnification 25x).
doi:10.1371/journal.pone.0140970.g005
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bladder cancer, additional diagnostic tools might be useful. Therefore, we routinely perform
bladder washing cytology during urethro-cystoscopy as Stonehill et al. reported good sensitiv-
ity (71%) and high specificity (97%) for diagnosis of bladder cancer in SCI patients [17]. As
unspecific multifocal flat lesions of the bladder mucosa can often be found by urethro-cystos-
copy in patients suffering from NLUTD, particularly in patients with chronic indwelling cathe-
ter due to chronic irritation/inflammation, bladder-washing cytology might be a good
indicator for the presence of carcinoma in situ (CIS) leading to subsequent biopsy and treat-
ment. Nevertheless, the limitation of cytology concerning the high rate of false negative results
in detecting low-grade tumors [17] must be taken into consideration.
In the present study using surveillance urethro-cystoscopy, relevant histological findings
varied widely and included bladder melanosis, nephrogenic adenoma, keratinizing squamous
metaplasia, intestinal metaplasia, and mucus-producing adenocarcinoma. Considering the fact
that relevant histological findings were present even in 15% (2/13) of the patients with NLUTD
who voided spontaneously, NLUTD itself might be a risk factor for the development of bladder
cancer as suggested by Kalisvaart et al. [18].
Although a relevant high percentage (45%) of patients was exposed to at least one risk factor
for bladder cancer, we did not find any dysplastic lesions. Bladder melanosis (Fig 1), a rare
entity with less than 20 cases reported up to date, is characterized by abnormal/excessive
deposits of melanin in the urothelium without any signs of atypia [19]. In general, bladder mel-
anosis is considered to be a benign lesion but it has been described as a potential premalignant
factor associated with primary melanoma of the bladder [20], high grade transitional cell carci-
noma of the bladder [21] and the upper urinary tract [19]. Although our patient with bladder
melanosis suffered from NLUTD due to cerebral palsy, it is unknown, if there is a causal rela-
tionship between NLUTD and the development of bladder melanosis or if it is just a coinciden-
tal histological finding. Nephrogenic adenoma (Fig 2) is an uncommon metaplastic lesion of
the urothelium found in all locations of the urinary tract often with multifocal appearance and
most commonly seen in the urinary bladder [22, 23]. Etiology and biological potential are still
unclear, but it seems to be attributed to urothelial irritation by trauma, previous surgery, uri-
nary calculi, radiation, chronic infections and urinary catheterization [22, 23]. Clinical symp-
toms, when present, are non-specific such as lower urinary tract symptoms and hematuria [22,
23]. Therapeutic options vary from watchful waiting to cystectomy [23], whereas in most cases
a transurethral resection is favored [24], as it was the case in our 3 patients with a nephrogenic
adenoma. A high recurrence rate up to 80% has been reported [23]. Although nephrogenic ade-
noma is usually thought to be a benign entity [22], there might be some potential for malignant
transformation as its occurrence has been reported in association with transitional cell carci-
noma [23] and moderately differentiated adenocarcinoma of the bladder in a patient with
NLUTD [24]. Because of the high recurrence rate of the nephrogenic adenoma and its assumed
potential for neoplastic transformation, regular follow-up should be considered. Keratinizing
squamous metaplasia (Fig 3) is rare and characterized by a replacement of the urothelial layer
with stratified keratinizing squamous epithelium due to chronic inflammation/irritation of the
bladder mucosa caused by different predisposing factors such as urinary tract infections,
indwelling catheters, fistula, urinary calculi, bladder outlet obstruction, bladder extrophy and
neurogenic bladder [25]. Keratinizing squamous metaplasia of the bladder is postulated to be a
pre-malignant condition leading to a higher risk of the development of bladder cancer, espe-
cially if dysplasia and/or extensive keratinization is present [26]. Most commonly, keratinizing
squamous metaplasia of the bladder is associated with co-existing or subsequent squamous cell
carcinoma and transitional cell carcinoma [27]. The risk of developing bladder cancer [26] in
patients with keratinizing squamous metaplasia of the bladder is high as progression has been
reported in 27% with a variable period of latency between 4 and 28 years [27]. In keratinizing
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squamous metaplasia of the bladder, a complete transurethral resection is considered to be the
therapy of choice [26] and a close follow-up using urethro-cystoscopy and bladder washing
cytology is highly advocated in order to detect malignant transformation at early stages [27].
Intestinal metaplasia (Fig 4) of the bladder is characterized by the presence of intestinal-
type epithelium and/or goblet cells in the bladder urothelium and is suggested to occur as a
result of chronic inflammation and irritating stimuli such as urinary tract infections, calculi,
neurogenic bladder, bladder extrophy, and long-term catheterization [25, 28]. Clinical symp-
toms reported by patients contain hematuria, dysuria, urgency and mucusuria as a sign of
mucus production/secretion of these lesions [25, 28]. Intestinal metaplasia of the bladder is
often associated with adenocarcinoma of the bladder [28] implying pre-malignant characteris-
tics [25] comparable to Barrett’s metaplasia of the esophagus [29]. Thus, considering the
potential of intestinal metaplasia to progress to a malignant condition such as adenocarcinoma
of the bladder, we regularly perform urethro-cystoscopy and bladder washing cytology in such
patients to ensure an early detection of malignant transformation. Importantly, patients with
SCI have a higher risk to develop bladder cancer compared to the general population [18]. We
agree with the existing literature [6], that bladder cancer appears to be a late complication in
patients suffering from NLUTD due to SCI, i.e. bladder cancer was detected in our patient 33
years post-injury.
In patients with muscle-invasive bladder cancer, bilateral pelvic lymphadenectomy and rad-
ical cystectomy combined with urinary diversion is mandatory as in our SCI patient with co-
existing intestinal metaplasia and mucus-producing adenocarcinoma of the bladder (Fig 5).
Patients with NLUTD require an extensive and specific work-up before embarking on an
individualized therapy taking into account the patients’ medical and physical condition as well
as their expectations [30]. Considering the high incidence of relevant histological findings in
the present study, surveillance urethro-cystoscopy and bladder washing cytology might be war-
ranted. While awaiting the results of well-designed risk-stratification studies, we recommend
performing surveillance urethro-cystoscopy and bladder washing cytology on patients suffer-
ing from NLUTD for at least 5 years on a regular short-term basis, that is, every 1 to 2 years.
This has also been suggested in a very recent retrospective study of surveillance urethro-cystos-
copy in SCI patients relying on an indwelling urethral or suprapubic catheter [31]. Although
our recommendation is not yet based on high-evidence level studies, this policy seems justified
considering the highly relevant, potentially life threatening consequences of not detecting and
consequently not treating a pre-malignant and/or malignant lesion.
Metaplastic lesions such as nephrogenic adenoma, keratinizing squamous metaplasia and
intestinal metaplasia may progress to a malignant condition but the underlying mechanisms
involved are unclear and remain to be elucidated. Given the heterogeneous nature and manage-
ment of neurogenic LUTD, it would be of great interest to know which sub-group of patients is
at highest risk to develop relevant histological lesions. In addition, further studies are needed to
determine the ideal starting point and frequency of surveillance urethro-cystoscopy. Thus, pro-
spective large-scale multicenter studies are highly warranted to investigate these still unan-
swered questions and to further improve the management of patients with NLUTD.
Study Limitations
The present study has some limitations. Although we evaluated a well-defined patient popula-
tion with NLUTD, there are limitations that should be addressed. Most of our patients suffered
from SCI, that is, patients with other neurological disorders were under-represented. Our unit
is part of a highly specialized university SCI center so that a negative selection bias, that is,
inclusion of more severe cases, cannot to be completely ruled out. Considering that we only
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studied patients suffering from NLUTD for at least 5 years, it is unclear whether the results
could be extrapolated to patients with a shorter exposure time to the neurological disease. Due
to the cross-sectional study design, randomization was not possible and patients with versus
without surveillance urethro-cystoscopy could not be compared. Moreover, because of the lim-
ited patient number in some groups, we did not perform sub-group analysis. Nevertheless, the
present study was prospective and representative of daily clinical practice.
Conclusions
In patients suffering from NLUTD for at least 5 years, we detected suspicious urethro-cystos-
copy and/or bladder washing cytology findings in 10% and relevant histological findings in 5%.
The relevant histological findings varied widely, that is, from bladder melanosis to muscle-
invasive mucus-producing adenocarcinoma of the bladder. Considering the important per-
centage of clinically relevant findings, surveillance urethro-cystoscopy might be warranted.
However, we cannot conclude from our data which sub-group of patients with NLUTD would
profit most from surveillance urethro-cystoscopy. In addition, starting point and frequency of
surveillance urethro-cystoscopy remain unclear. Thus, further well-designed, adequately pow-
ered and sampled prospective studies are needed to investigate these highly relevant issues.
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